Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

What are Viruses?00:50

What are Viruses?

128.2K
Overview
128.2K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

280
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
280
Hepatic Portal System01:21

Hepatic Portal System

5.9K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.9K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

299
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
299
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

244
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
244
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

581
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
581

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Metabolites to Chromatin: ACSS2-Driven Acetyl-CoA Fuels H3K27ac Chromatin Remodeling in HBV-Associated HCC.

Clinical and molecular hepatology·2026
Same author

SCITO-seq2: ultra-high-throughput single-cell transcriptome and epitope sequencing.

Genome biology·2026
Same author

Pantothenate kinase 4 controls lipid synthesis for T-cell proliferation by modulating coenzyme A and glutaminolysis.

Signal transduction and targeted therapy·2025
Same author

Notch2-expressing CD4<sup>+</sup> T cells attain immunoregulatory functions during autoimmune inflammation.

Cellular & molecular immunology·2025
Same author

Author Correction: ZIP8 exacerbates collagen-induced arthritis by increasing pathogenic T cell responses.

Experimental & molecular medicine·2025
Same author

Javanicin inhibits the secretion of hepatitis B virus particles thorough the proteasome-dependent degradation of core protein.

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi·2025

Related Experiment Video

Updated: Feb 4, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Mouse models for hepatitis B virus research.

Jeong-Ryul Hwang1, Sung-Gyoo Park1

  • 1School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, Korea.

Laboratory Animal Research
|October 13, 2018
PubMed
Summary

Hepatitis B virus (HBV) infection affects millions globally. This review details mouse models, like transgenic and chimeric mice, developed to overcome limitations of primate models for studying HBV therapies in vivo.

Keywords:
FRGHepatitis B virusalb-uPA/SCIDmouse model

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K

Related Experiment Videos

Last Updated: Feb 4, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K

Area of Science:

  • Hepatology
  • Virology
  • Translational Medicine

Background:

  • Hepatitis B virus (HBV) infection is a significant global health issue with 250 million carriers.
  • Primates are susceptible to HBV but are unsuitable animal models due to ethical, cost, and size constraints.
  • The lack of appropriate in vivo models hinders the development of HBV therapies.

Purpose of the Study:

  • To review and summarize currently available mouse model systems for studying Hepatitis B virus in vivo.
  • To address the need for suitable animal models in HBV research.

Main Methods:

  • Review of existing literature on HBV mouse models.
  • Summary of four main types of mouse models: HBV transgenic mice, hydrodynamic injection-mediated HBV replicon delivery systems, adeno-associated virus-mediated HBV replicon delivery systems, and human liver chimeric mouse models.

Main Results:

  • Several mouse model systems for HBV research are available and under development.
  • These models include transgenic mice, hydrodynamic injection systems, AAV delivery systems, and chimeric mice.
  • These models show promise for in vivo studies of HBV.

Conclusions:

  • Developed mouse models offer viable alternatives to primate models for HBV research.
  • These models are crucial tools for advancing the study of HBV and the development of new therapies.